<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="25">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03106532</url>
  </required_header>
  <id_info>
    <org_study_id>PHP-201-S203</org_study_id>
    <nct_id>NCT03106532</nct_id>
  </id_info>
  <brief_title>Evaluation of PHP-201 Ophthalmic Solution in Patients With Normal Tension Glaucoma</brief_title>
  <official_title>A Multicenter, Randomized, Placebo-controlled, Double-blind, Dose-finding Phase 2 Clinical Trial to Evaluate the Efficacy in Reduction of Intraocular Pressure and Safety of PHP-201 in Patients With Normal Tension Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>pH Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>pH Pharma</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the optimal dose for the efficacy in reduction of intraocular pressure and
      safety of PHP-201 ophthalmic solution in patients with normal tension glaucoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Data collection (electronic case report forms), Data dictionary (MedDRA)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 6, 2017</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean diurnal IOP change from baseline at post-treatment time point of 4 weeks</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of patient with adverse events</measure>
    <time_frame>28 days</time_frame>
    <description>The number of patient with adverse events including ocular adverse events</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">138</enrollment>
  <condition>Normal Tension Glaucoma</condition>
  <arm_group>
    <arm_group_label>PHP-201 0.25% ophthalmic solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PHP-201 0.25% ophthalmic solution, TID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PHP-201 0.5% ophthalmic solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PHP-201 0.5% ophthalmic solution, TID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo ophthalmic solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo ophthalmic solution, TID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PHP-201 0.25% ophthalmic solution</intervention_name>
    <description>3 drops daily, 28 days</description>
    <arm_group_label>PHP-201 0.25% ophthalmic solution</arm_group_label>
    <other_name>PHP-201</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PHP-201 0.5% ophthalmic solution</intervention_name>
    <description>3 drops daily, 28 days</description>
    <arm_group_label>PHP-201 0.5% ophthalmic solution</arm_group_label>
    <other_name>PHP-201</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo ophthalmic solution</intervention_name>
    <description>3 drops daily, 28 days</description>
    <arm_group_label>Placebo ophthalmic solution</arm_group_label>
    <other_name>PHP-201</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  19 years and older, female and male

          -  IOP ≤21 mmHg

          -  Subject showing open angle finding, glaucomatous optic nerve damage and visual field
             defects

          -  BCVA ≥+0.2

        Exclusion Criteria:

          -  Subject with the disease and surgery history that are not eligible to participate
             (acute closed angle glaucoma, narrow angle glaucoma, advanced glaucomatous loss,
             ocular trauma, eye surgery or laser surgery, unstable angina, myocardial infarction,
             uncontrolled hypertension and diabetes, etc)

          -  Subject who can't discontinue contact lenses

          -  Subject who can't discontinue topical/systemic IOP lowering medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Soojin Kim</last_name>
    <role>Study Director</role>
    <affiliation>pH Pharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Soojin Kim</last_name>
    <phone>82-2-3706-4321</phone>
    <email>soojin.kim@ph-pharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>KiHo Park, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>April 7, 2017</lastchanged_date>
  <firstreceived_date>March 30, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Low Tension Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
